Phase Forward Chairman and Founder Honored By PharmaVOICE
Posted on: Monday, 15 August 2005, 12:00 CDT
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Paul Bleicher, M.D., Ph.D, chairman and founder, has been named to the PharmaVOICE 100. Sponsored by PharmaVOICE magazine, the listing recognizes the people in the life sciences industry who have the greatest influence on corporate leadership, research and development, technology, creativity, and strategy.
"The inaugural issue of the PharmaVOICE 100 is dedicated to the unique individuals who have been recognized by the readers of PharmaVOICE for the inspiration and motivation they offer those around them, their influence as corporate leaders, and the positive impact their actions have had on the industry," said Taren Grom, PharmaVOICE editor. "PharmaVOICE recognizes that the life sciences industry's contributions to improving people's lives are more than products and services, and that there are strong, inspiring, and motivating people behind the strategies, business decisions, and tactics that move the industry forward. We are honored to showcase these individuals who are making a difference."
Since founding Phase Forward in 1997, Dr. Bleicher has served in various roles within the company, including CEO and president. He helped build the organization from its inception, and his vision continues to guide Phase Forward into new areas serving the clinical data needs of pharmaceutical, biotechnology, and medical device companies.
"It is not possible to discuss clinical data management solutions for clinical trials without including Phase Forward and Paul in the conversation. Since the beginning of the critical evolution from paper-based processes to the adoption of electronic data collection and e-clinical technologies, Paul has been an extremely insightful and influential voice," said Ken Getz, founder and chairman of the Center for Information and Study on Clinical Research Participation (CISCRP) and a research fellow at the Tufts Center for the Study of Drug Development. "Paul's inclusion in this listing recognizes and highlights his innovative efforts on behalf of Phase Forward, the clinical research enterprise, and the life sciences industry as a whole."
Dr. Bleicher has been involved in drug development for almost 20 years. Prior to founding Phase Forward, he worked as an investigator in industry-sponsored trials at Harvard Medical School, as a medical monitor at a leading CRO, and as vice president, clinical affairs at a biotechnology company. Dr. Bleicher has been very active in the leadership of the Drug Information Association (DIA) and on the editorial board of three leading industry journals. In 2004, he was the recipient of an Outstanding Service Award from the DIA. Dr. Bleicher also serves as a member of the School of Science External Advisory Committee at Rensselaer Polytechnic Institute, and received their alumni association's prestigious Fellows Award in 2003. In 2002, Dr. Bleicher was named an Entrepreneur of the Year by Ernst & Young, and received an Innovator's Award from the Small Business Association of New England (SBANE).
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company helps pharmaceutical, biotechnology, and medical device companies bring needed drugs and therapies to market faster and more safely. Phase Forward offers proven solutions in electronic data capture (EDC), clinical data management (CDM), and adverse event reporting (AER). Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 220 organizations worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, GlaxoSmithKline, Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, Schering-Plough Research Institute, and Serono. Additional information about Phase Forward is available at www.phaseforward.com.
Source: Business Wire
Related Articles
- Vantia Therapeutics' VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea Phase I Results Show VA111913 to be Safe and Well Tolerated
- Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients With Multiple Sclerosis
- Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial
- Forest Laboratories Announces Positive Phase III Data for Alzheimer's Drug
- Watson Reports Positive Phase III Data for Prostate and Bladder Drugs
- Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
- ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
- New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
- BioAlliance Pharma Announces Preliminary Phase III Data On Miconazole Lauriad Bioadhesive Buccal Tablets For Local Treatment of Oropharyngeal Candidiasis in Head and Neck Cancer Patients Following Radiation Therapy
 |
 |
User Comments (0)
RSS Feeds